Please find below some of the recent articles that have been co-authored by AKESOgen scientists.

Thermo Fisher Scientific Showcases Large-scale Precision Medicine Research Studies in Genotyping

Thermo Fisher Scientific Showcases Large-scale Precision Medicine Research Studies in Genotyping

http://www.prweb.com/releases/2017/09/prweb14726130.htm

In this webinar, which LabRoots will host October 25, attendees will gain a better understanding of how the recently developed Axiom Precision Medicine Research Array can be used in a wide variety of disease and therapeutic research areas.

Yorba Linda, Ca (PRWEB) September 27, 2017 — As more is discovered about the implications of genetic variation in 21st century medicine, the utilization of genotyping as a molecular tool both in the research and clinical setting is as important and popular as ever. This presentation will exemplify the power and precision of the Applied BiosystemsTM AxiomTM Genotyping Platform in several settings.

In this webinar, which is sponsored by Thermo Fisher Scientific, participants will learn of the flexibility and accuracy of the Axiom Genotyping platform through comprehensive demonstration, as well as how it can be used to power large-scale genomic studies. They will learn about and discuss the Applied BiosystemsTM PharmacoScan Solution for pharmacogenomics research and its usefulness in clinical research trials for stratifying populations.

Examples will include the use of Applied BiosystemsTM AxiomTM Genotyping Arrays in the Department of Veterans Affairs’ Million Veteran Program (MVP), the use of the Applied BiosystemsTM AxiomTM Precision Medicine Research Array, the use of the PharmacoScan Solution for pharmacogenetics, as well as using a unique custom array for potential dementia risk assessment.

Dr. Mark Bouzyk, co-founder and CSO of AKESOgen, Inc., will be the speaker for this event.

Bouzyk currently serves as co-founder and chief scientific officer of AKESOgen, Inc., a genomics, pharmacogenomics and biobanking company. Prior to AKESOgen, he spent five years as a faculty member in the Department of Human Genetics at Emory University. Bouzyk earned his doctorate degree in human molecular genetics from the University of Hertfordshire; his interests lie in Pharmacogenetics as well as candidate gene and genomic association studies to identify genes for both common and rare diseases.

For Research Use Only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

About LabRoots

LabRootsis the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

Brian Leyland-Jones, Kathryn P. Gray, Mark Abramovitz, Mark Bouzyk, Brandon Young, Bradley Long, Roswitha Kammler, Patrizia Dell’Orto, Beat Thürlimann, Vernon Harvey, Patrick Neven, Laurent Arnould, Rudolf Maibach, Karen N. Price, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber, Olivia Pagani, Giuseppe Viale, James M. Rae and Meredith M. Regan; on behalf of the BIG 1-98 Collaborative Group.

Breast Cancer Res Treat. 2015 Dec;154(3):543-55.

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

CYP19A1 polymorphisms and clinical outcomes
in postmenopausal women with hormone receptor-positive
breast cancer in the BIG 1–98 trial

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell’Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Harvey VJ,Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM.

Breast Cancer Res Treat. 2015 Jun;151(2):373-84. doi: 10.1007/s10549-015-3378-3. Epub 2015 May 3.

PMID:24814193

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

Mutations in EMP2 cause childhood-onset nephrotic syndrome

Mutations in EMP2 cause childhood-onset nephrotic syndrome.

Gee HY, Ashraf S, Wan X, Vega-Warner V, Esteve-Rudd J, Lovric S, Fang H, Hurd TW, Sadowski CE, Allen SJ, Otto EA, Korkmaz E, Washburn J, Levy S, Williams DS, Bakkaloglu SA, Zolotnitskaya A, Ozaltin F, Zhou W, Hildebrandt F.

Am J Hum Genet. 2014 Jun 5;94(6):884-90. doi: 10.1016/j.ajhg.2014.04.010. Epub 2014 May 8.

PMID: 24814193

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

Wnt signaling in triple negative breast cancer is associated with metastasis.

Wnt signaling in triple negative breast cancer is associated with metastasis.

Dey N, Barwick BG, Moreno CS, Ordanic-Kodani M, Chen Z, Oprea-Ilies G, Tang W, Catzavelos C, Kerstann KF, Sledge GW Jr, Abramovitz M, Bouzyk M, De P, Leyland-Jones BR.

BMC Cancer. 2013 Nov 10;13:537. doi: 10.1186/1471-2407-13-537.

PMID: 24209998 [PubMed – in process] Free Article

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner

Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.

Dey N, Young B, Abramovitz M, Bouzyk M, Barwick B, De P, Leyland-Jones B.

PLoS One. 2013 Oct 15;8(10):e77425. doi: 10.1371/journal.pone.0077425. eCollection 2013.

PMID: 24143235 [PubMed – indexed for MEDLINE]Free Article

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell’orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group.

J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.

PMID: 22395644 [PubMed – indexed for MEDLINE] Free PMC Article

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail